Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Optical Biosensors Are Increasingly Used at Point-of-Care and in Medical Laboratories

In clinical practices, optical biosensors are becoming more prevalent in point-of-care testing and in-house medical laboratories. One primary reason for their increased adoption is optical biosensors are non-invasive, alleviating the pain and inconvenience for patients when drawing blood. In addition, before this technology, many analyses had to be performed using large equipment located in central…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

In clinical practices, optical biosensors are becoming more prevalent in point-of-care testing and in-house medical laboratories. One primary reason for their increased adoption is optical biosensors are non-invasive, alleviating the pain and inconvenience for patients when drawing blood. In addition, before this technology, many analyses had to be performed using large equipment located in central laboratories, causing delays in diagnosis. Let’s take a look at the future of optical sensing at point-of-care and in medical laboratories.

Biosensors Are Used in a Wide Variety of Applications

Simply put, a biosensor is a self-contained analytical device combining a biological element with a physicochemical component to generate a measurable signal for further analysis. In recent years, biosensors have become more widely used in medical diagnostics and biotechnology, as well as in pharmaceuticals, food, beverage, environmental, and agricultural industries. This is due to their simplicity in operation, higher sensitivity, ability to perform multiplex analysis, and capability to be integrated with different functions by the same computer chip.

Biosensors are highly responsive, making them ideal for sensing real-time signals from the production of biomolecules. Blood glucose monitoring is one of the most popular applications of biosensors in recent years. Also, biosensors are used in clinical laboratories to detect lactate, peroxides, and cytokines, as well as the release of proteins or antibodies in different inflammatory diseases and tumors.

New Biosensor Technology Will Lead to Increased Adoption

Since the development of the first oxygen biosensor in 1962, there have been enormous strides in biosensor technology. Even so, the practical application of biosensors in the field of medicine is still in its infancy. Further growth will be driven by the creation of devices that are able to provide results at or near the patient efficiently.

In order to increase their adoption, these devices need further advancement regarding simplicity, sensitivity, multiplex analysis of multiple biomarkers, and integration of different functions by the same computer chip. This will allow non-laboratory personnel like nurses and respiratory therapists to perform testing directly at point-of-care. Additionally, in-house laboratories will gain the greater capability to perform more sophisticated testing that once had to outsourced to large industrial laboratories. This will result in more rapid turnaround times for test results, reduced costs, and higher patient satisfaction.

Fiberguide is Helping to Drive the Advancement of Biosensors

For biosensors to become more powerful and user-friendly, there must be continuous development in optical fiber technology. Fiberguide manufactures over 500 different specialty optical fibers packaged in a variety of assemblies and bundles for optical power delivery and optical sensing applications. Fiberguide has proved their commitment to reliable, long-term, strategic partnerships with OEM manufacturers, providing efficient, cost-effective, practical fiber optic solutions engineered to meet specific needs.

Read more at fiberguide.com

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Automation adoption gap widens in US manufacturing as medtech presses ahead

Automation adoption gap widens in US manufacturing as medtech presses ahead

Automation in US manufacturing lags, with 80% of factories lacking automation tools. In contrast, medtech manufacturers are advancing with technologies like micro-molding and ultrasonic welding. This disparity highlights a growing gap in technology adoption across different sectors.

  • 0180% of US factories have no automation.
  • 02Medtech manufacturers are investing in automation technologies.
  • 03There's an increasing divide in technology adoption across industries.

Jul 12, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512